FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767064775> ?p ?o ?g. }

• W2767064775 endingPage "97786" @default.
• W2767064775 startingPage "97769" @default.
• W2767064775 abstract "// Inna Chen 1 , Victoria M. Raymond 2 , Jennifer A. Geis 2 , Eric A. Collisson 3 , Benny V. Jensen 1 , Kirstine L. Hermann 4 , Mark G. Erlander 2 , Margaret Tempero 3 and Julia S. Johansen 1, 5, 6 1 Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark 2 Trovagene, Inc., San Diego, California, USA 3 Department of Medicine, University of California San Francisco, San Francisco, California, USA 4 Department of Radiology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark 5 Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark 6 Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Correspondence to: Inna Chen, email: Inna.Chen@regionh.dk Victoria M. Raymond, email: vraymond@trovagene.com Keywords: ctDNA; KRAS; pancreatic ductal adenocarcinoma; CA19-9; prognostic biomarker Received: January 17, 2017      Accepted: October 11, 2017      Published: October 26, 2017 ABSTRACT Precision oncology requires sensitive and specific clinical biomarkers. Carbohydrate Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks sensitivity and specificity. Nearly all PDAs harbor somatic KRAS mutations, nominating circulating tumor DNA (ctDNA) KRAS as an alternative disease biomarker, however, variable clinical performance has limited its clinical utility. We applied an ultrasensitive, PCR mutation enrichment, next generation sequencing ctDNA KRAS assay in a large cohort of patients with unresectable PDA ( N = 189) recruited to the BIOPAC study between 2008–2015. Baseline and longitudinal serum CA19-9 and plasma ctDNA KRAS were correlated with time to progression (TTP) and overall survival (OS). Baseline ctDNA KRAS detection rate was 93.7% (86.4% in patients with non-elevated CA19-9). ctDNA KRAS and CA19-9 were positively correlated yet independently associated with TTP and OS (ctDNA KRAS p = 0.0018 and 0.0014; CA19-9 p = 0.0294 and 0.0007, respectively). A generated model quantitating longitudinal ctDNA KRAS correctly assessed greater than 80% of patient responses. Quantitative detection of KRAS ctDNA is an informative prognostic biomarker, complementary to CA19-9 in patients with unresectable PDA. Longitudinal ctDNA KRAS may inform therapeutic decision making and provides a kinetically dynamic and quantitative metric of patient response." @default.
• W2767064775 created "2017-11-10" @default.
• W2767064775 creator A5003109423 @default.
• W2767064775 creator A5004947197 @default.
• W2767064775 creator A5009447909 @default.
• W2767064775 creator A5035793503 @default.
• W2767064775 creator A5063670944 @default.
• W2767064775 creator A5071985590 @default.
• W2767064775 creator A5072641295 @default.
• W2767064775 creator A5075723539 @default.
• W2767064775 creator A5089311886 @default.
• W2767064775 date "2017-10-26" @default.
• W2767064775 modified "2023-09-23" @default.
• W2767064775 title "Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma" @default.
• W2767064775 cites W1483158525 @default.
• W2767064775 cites W1507991646 @default.
• W2767064775 cites W1568187088 @default.
• W2767064775 cites W1592992548 @default.
• W2767064775 cites W1729732057 @default.
• W2767064775 cites W1825978543 @default.
• W2767064775 cites W1849446486 @default.
• W2767064775 cites W1914351667 @default.
• W2767064775 cites W1935378439 @default.
• W2767064775 cites W1945319061 @default.
• W2767064775 cites W1967479446 @default.
• W2767064775 cites W1983441649 @default.
• W2767064775 cites W1987313243 @default.
• W2767064775 cites W1995740214 @default.
• W2767064775 cites W1998036846 @default.
• W2767064775 cites W1998516681 @default.
• W2767064775 cites W2019607817 @default.
• W2767064775 cites W2019867275 @default.
• W2767064775 cites W2027735722 @default.
• W2767064775 cites W2032579588 @default.
• W2767064775 cites W2034983280 @default.
• W2767064775 cites W2039896904 @default.
• W2767064775 cites W2044548139 @default.
• W2767064775 cites W2066681450 @default.
• W2767064775 cites W2067826589 @default.
• W2767064775 cites W2069786312 @default.
• W2767064775 cites W2072786828 @default.
• W2767064775 cites W2084795687 @default.
• W2767064775 cites W2102245227 @default.
• W2767064775 cites W2115699038 @default.
• W2767064775 cites W2117809360 @default.
• W2767064775 cites W2130858403 @default.
• W2767064775 cites W2134640949 @default.
• W2767064775 cites W2135184154 @default.
• W2767064775 cites W2139224474 @default.
• W2767064775 cites W2147243980 @default.
• W2767064775 cites W2151253787 @default.
• W2767064775 cites W2153704693 @default.
• W2767064775 cites W2159007127 @default.
• W2767064775 cites W2164034599 @default.
• W2767064775 cites W2165480504 @default.
• W2767064775 cites W2171237493 @default.
• W2767064775 cites W2176175311 @default.
• W2767064775 cites W2207038926 @default.
• W2767064775 cites W2280092090 @default.
• W2767064775 cites W2324165948 @default.
• W2767064775 cites W2414965726 @default.
• W2767064775 cites W2466792968 @default.
• W2767064775 cites W2479380037 @default.
• W2767064775 cites W2516846277 @default.
• W2767064775 cites W2534003457 @default.
• W2767064775 cites W2554873133 @default.
• W2767064775 cites W2566484518 @default.
• W2767064775 cites W2573891764 @default.
• W2767064775 cites W4210976084 @default.
• W2767064775 doi "https://doi.org/10.18632/oncotarget.22080" @default.
• W2767064775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5716690" @default.
• W2767064775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29228650" @default.
• W2767064775 hasPublicationYear "2017" @default.
• W2767064775 type Work @default.
• W2767064775 sameAs 2767064775 @default.
• W2767064775 citedByCount "25" @default.
• W2767064775 countsByYear W27670647752018 @default.
• W2767064775 countsByYear W27670647752019 @default.
• W2767064775 countsByYear W27670647752020 @default.
• W2767064775 countsByYear W27670647752021 @default.
• W2767064775 countsByYear W27670647752022 @default.
• W2767064775 countsByYear W27670647752023 @default.
• W2767064775 crossrefType "journal-article" @default.
• W2767064775 hasAuthorship W2767064775A5003109423 @default.
• W2767064775 hasAuthorship W2767064775A5004947197 @default.
• W2767064775 hasAuthorship W2767064775A5009447909 @default.
• W2767064775 hasAuthorship W2767064775A5035793503 @default.
• W2767064775 hasAuthorship W2767064775A5063670944 @default.
• W2767064775 hasAuthorship W2767064775A5071985590 @default.
• W2767064775 hasAuthorship W2767064775A5072641295 @default.
• W2767064775 hasAuthorship W2767064775A5075723539 @default.
• W2767064775 hasAuthorship W2767064775A5089311886 @default.
• W2767064775 hasBestOaLocation W27670647751 @default.
• W2767064775 hasConcept C121608353 @default.
• W2767064775 hasConcept C126322002 @default.
• W2767064775 hasConcept C143998085 @default.
• W2767064775 hasConcept C2780210213 @default.
• W2767064775 hasConcept C2781187634 @default.

• next